Lack of efficacy of vinblastine and cisplatin in patients with progressive small cell carcinoma of the lung.

Abstract

Twenty patients with small cell carcinoma of the lung resistant to primary therapy, or relapsing after an objective response to initial treatment, were treated with vinblastine plus high-dose cisplatin chemotherapy. One patient achieved a partial remission lasting 4 months, while 19 patients had no objective response to this regimen. The median survival from the time of disease progression to death was 2.5 months (range, 1-7), with an overall median survival of 13 months (range, 5-31; diagnosis to death). In our patients, vinblastine plus cisplatin given as salvage therapy did not produce a significant response rate or survival prolongation.

• Authors: S B Newman, J D Bitran, P C Hoffman, V Raghaven, T R DeMeester, H M Golomb
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 67 Issue 9 Pg. 831-2 (Sep 1983) ISSN: 0361-5960 [Print] United States
• PMID: 6309381 (Publication Type: Journal Article)

Chemical References

• Vinblastine
• Cisplatin

Topics

• Adult
• Aged
• Carcinoma, Small Cell (drug therapy)
• Cisplatin (administration & dosage, adverse effects)
• Drug Therapy, Combination
• Female
• Humans
• Lung Neoplasms (drug therapy)
• Male
• Middle Aged
• Vinblastine (administration & dosage, adverse effects)